Compare Incyte Corporation (INCY) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs PulteGroup, Inc. — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while PulteGroup, Inc. trades at $132.77 (market cap $25.22B). The key difference: Incyte Corporation and PulteGroup, Inc. are close in size by market cap, and PulteGroup, Inc. pays a 0.79% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PHM | |
|---|---|---|
Market Cap | $24.54B | $25.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $142.56 |
52-Week Low | $81.61 | $110.11 |
Enterprise Value | $20.04B | $25.64B |
Dividend Yield | — | 0.79% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
